BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
- Written by PR Newswire
![]() |
- BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody–drug conjugate (ADC) to enter clinical development.
- BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and...














